secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001558370-23-014088
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q2 2023 net loss $37.3M ($0.59/share); cash $341M; narsoplimab BLA path set
--------------------------------------------------------------------------------

- Net loss Q2 2023 $37.3M vs $30.8M prior year; six-month loss $71.0M; cash burn $30.1M.
- OMIDRIA royalties $10.7M on Rayner sales $35.7M; rate cut from 50% to 30% after $200M milestone.
- Cash, equivalents, and short-term investments $341.3M; accounts receivable $11.2M; runway into 2025.
- FDA Type B meeting; plan to submit detailed survival data analysis for narsoplimab BLA in TA-TMA; target mid-2024 decision.
- Phase 3 ARTEMIS-IGAN IgA nephropathy 9-month data expected later Q3 2023; OMS906 PNH trial shows positive interim results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000155837023014088/0001558370-23-014088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000155837023014088/omer-20230809x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer